Pay in 4 interest-free payments of $6.19 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
In 2005, the FDA approved exenatide (Byetta) for the treatment of type 2 diabetes mellitus
L-carnitine: investigational strategy for metabolic encephalopathy [PMID: 6478235] Laboratory literature summary: L-carnitine: investigational strategy for metabolic encephalopathy
Autoimmune disease: May contribute to combating autoimmune diseases
Pharmacological options with established evidence include acamprosate, naltrexone, and disulfiram for maintaining abstinence
US$ 26.96
US$ 27.50
US$ 29.85
US$ 22.90
US$ 20.67
US$ 23.92
US$ 27.35
